- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03301103
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli (APA12/PANTER)
PTM202 and Modulation of Host Resistance to Diarrheagenic Escherichia Coli in a Randomized, Double-blind, Placebo Controlled Study in Healthy Human Subjects
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The APA12/PANTER study is a randomized, double-blind, placebo-controlled, parallel intervention study of 3 weeks in 72 healthy adults. The study will include 2 arms; PTM202 and placebo. Subjects will be instructed to maintain their usual pattern of physical activity and their habitual food intake, but to standardize their dietary calcium intake. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
At study day 14, 15 and 16 subjects will receive either placebo or PTM202, a dietary formula containing dried bovine colostrum and dried whole egg.
Before and after the diarrheagenic E. coli challenge an online diary will be kept to record information on stool consistency, frequency, severity of symptoms and mediation intake. At various time points before and after diarrheagenic E. coli challenge stool samples will be collected. The main study parameters are Stool consistency (Bristol Stool Scale reported by the subjects in the online diary, and Percentage of fecal wet weight (% determined by freeze-drying).
Secondary study parameters are: Stool frequency (Stools per day reported by the subjects in the online diary), Total fecal wet weight (fecal weight in g/day), and the incidence and severity of Gastro-intestinal symptoms (Gastro-intestinal Symptom Rating Scale reported by the subjects in the online diary).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Gelderland
-
Ede, Gelderland, Holland, 6718ZB
- NIZO
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male;
- Age between 18 and 55 years;
- BMI ≥18 and ≤27 kg/m2;
- Healthy as assessed by the NIZO food research medical questionnaire.
- Ability to follow verbal and written instructions;
- Availability of internet connection;
- Signed informed consent;
- Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned;
- Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for at least 15 years;
- Willing to comply with study procedures, including collection of stool samples;
- Willingness to abstain from high calcium containing products;
- Willingness to abstain from alcoholic beverages three days before, during and for four days after diarrheagenic E. coli challenge;
- Willingness to abstain from antibiotics, norit, laxatives, nonsteroidal anti-inflammatory drugs (OTC), opiates, antacids, proton pump inhibitors, and antimotility agents (e.g., loperamide) on the three days before, during and for four days after diarrheagenic E. coli challenge.
- Willingness to abstain from probiotics three days before, during and for four days after diarrheagenic E. coli challenge;
- Willingness to give up blood donation starting 1 month prior to study start and during the entire study;
Exclusion Criteria:
- Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus infection (HIV);
- Disease of the GI tract, liver, bile bladder, kidney, thyroid gland (self-reported);
- Diarrheagenic E. coli strain (as used in the study) detected in fecal sample at screening;
- Evidence of current excessive alcohol consumption or non-therapeutic drug (ab)use);
- High titer serum antibodies against CFA-II diarrheagenic E. coli strain (as used in the study) at screening;
- History of microbiologically confirmed ETEC or cholera infection in last 3 years;
- Known allergy to the following antibiotics: ciprofloxacin, trimethoprim-sulfamethoxazole, and penicillins;
- Known allergy to soy, milk- and/or egg;
- Mental status that is incompatible with the proper conduct of the study;
- Occupation involving handling of ETEC or Vibrio cholerae currently, or in the past 3 years;
- Reported average stool frequency of <1 or >3 per day;
- Symptoms consistent with Travelers' Diarrhea concurrent with travel to countries where ETEC infection is endemic (most of the developing world) within 3 years prior to dosing, OR planned travel to endemic countries during the length of the study;
- Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion), cholesterol lowering agents, antacids, proton pump inhibitors and immune suppressive agents (up till 3 months prior to inclusion);
- Vaccination for or ingestion of ETEC, cholera, or E coli heat labile toxin within 3 years prior to inclusion;
- Vegans.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Placebo
The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14). |
After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
|
Eksperimentel: PTM202
PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg. After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14). |
After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Stool consistency
Tidsramme: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in stool consistency score (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Relative fecal wet weight
Tidsramme: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in relative fecal wet weight (freeze-drying) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Stool frequency
Tidsramme: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in stool frequency (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Total fecal wet weight
Tidsramme: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in total fecal wet weight (wet weight measurement) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Gastro-intestinal symptoms
Tidsramme: Before challenge (Day 11-13), After challenge (Day 14-18)
|
Change in gastro-intestinal symptoms (questionnaire) before and after E. coli challenge
|
Before challenge (Day 11-13), After challenge (Day 14-18)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Van Schaik, NIZO food research
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NL62453.028.17
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Rejsendes diarré
-
Merck Sharp & Dohme LLCAfsluttetClostridium Difficile Associated Diarrhea (CDAD)
-
Merck Sharp & Dohme LLCAfsluttetClostridium Difficile Associated Diarrhea (CDAD)
Kliniske forsøg med E. coli strain E1392-75-2A
-
NIZO Food ResearchFrieslandCampinaAfsluttet
-
NIZO Food ResearchAfsluttetGastroenteritis | Diarré | Bakterielle infektioner | Escherichia coli infektionerHolland
-
PATHTrukket tilbageShigella Sonnei dysenterierForenede Stater
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)AfsluttetHepatitis C | ThalassæmiForenede Stater, Det Forenede Kongerige, Canada